Prime Medicine, Ownership

PRME Etf  USD 1.95  0.06  2.99%   
Prime Medicine, owns a total of 131.16 Million outstanding shares. Over half of Prime Medicine,'s outstanding shares are owned by third-party entities. These third-party entities are typically referred to as corporate investors that secure positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company maintains, if the real value of the etf is less than the current market value, you may not be able to make money on it.
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
  
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Prime Medicine, Common. Also, note that the market value of any etf could be closely tied with the direction of predictive economic indicators such as signals in population.

Prime Etf Ownership Analysis

The fund maintains 99.55% of assets in stocks. Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. Prime Medicine is listed under Biotechnology in the United States and is traded on NASDAQ Exchange exchange. To find out more about Prime Medicine, Common contact Keith MD at 617 465 0013 or learn more at https://primemedicine.com.

Top Etf Constituents

Prime Medicine, Common Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Prime Medicine, insiders, such as employees or executives, is commonly permitted as long as it does not rely on Prime Medicine,'s material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Prime Medicine, insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Schenkein David P over a week ago
Acquisition by Schenkein David P of 062 shares of Prime Medicine, at 14.83 subject to Rule 16b-3
 
Ann Lee over two weeks ago
Acquisition by Ann Lee of 275000 shares of Prime Medicine, at 2.42 subject to Rule 16b-3
 
Reine Allan over three weeks ago
Acquisition by Reine Allan of 275000 shares of Prime Medicine, at 2.42 subject to Rule 16b-3
 
Gv 2019 Gp, L.l.c. over two months ago
Disposition of 471 shares by Gv 2019 Gp, L.l.c. of Prime Medicine, at 14.7534 subject to Rule 16b-3
 
Reine Allan over three months ago
Acquisition by Reine Allan of 75000 shares of Prime Medicine, at 6.8 subject to Rule 16b-3
 
Reine Allan over three months ago
Acquisition by Reine Allan of 75000 shares of Prime Medicine, at 6.8 subject to Rule 16b-3
 
Cahill Thomas over three months ago
Acquisition by Cahill Thomas of 45000 shares of Prime Medicine, at 7.68 subject to Rule 16b-3
 
Meredith Goldwasser over three months ago
Acquisition by Meredith Goldwasser of 90498 shares of Prime Medicine, at 8.49 subject to Rule 16b-3
 
Keith Gottesdiener over three months ago
Disposition of 226925 shares by Keith Gottesdiener of Prime Medicine, subject to Rule 16b-3
 
Gv 2023 Gp, L.l.c. over six months ago
Discretionary transaction by Gv 2023 Gp, L.l.c. of tradable shares of Prime Medicine, subject to Rule 16b-3
 
Gv 2019 Gp, L.l.c. over six months ago
Disposition of 28100 shares by Gv 2019 Gp, L.l.c. of Prime Medicine subject to Rule 16b-3
 
Marrazzo Jeffrey D over six months ago
Acquisition by Marrazzo Jeffrey D of 45000 shares of Prime Medicine at 7.68 subject to Rule 16b-3

Prime Medicine, Outstanding Bonds

Prime Medicine, issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Prime Medicine, Common uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Prime bonds can be classified according to their maturity, which is the date when Prime Medicine, Common has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Prime Etf

Prime Medicine, financial ratios help investors to determine whether Prime Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Prime with respect to the benefits of owning Prime Medicine, security.